VivoSeq
Immunology

Hypereosinophilic Syndrome

16

Pipeline Programs↗

6

Active Trials↗

11

Companies Involved↗

Hypereosinophilic syndrome is an emerging landscape with 16 programs across 11 companies. The most active players are Novartis, Teva, Incyte. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

79/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

3 programs

Phase 2Teva logo

Teva

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2K

Karyopharm Therapeutics Inc

1 program

Phase 2A

Arog Pharmaceuticals, Inc.

1 program

Phase 2K

Knopp Biosciences

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

16programs
Small molecule956%
Monoclonal antibody531%
Protein / enzyme16%
Gene therapy16%

Modality classified for 95% of 19 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed11 · 48%
Recruiting4 · 17%
Unknown status3 · 13%
Terminated3 · 13%
Active, not recruiting2 · 9%

Clinical Trials

Trial Activity

23 trials

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Recruiting·—·Phase 2·NCT03801434·10 enrolled
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06477653·30 enrolled
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Recruiting·UUniversity Hospital, Lille·N/A·NCT04018118·600 enrolled
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Recruiting·GSK logoGSK·Phase 3·NCT05334368·123 enrolled
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00044304·70 enrolled
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT04191304·134 enrolled
Steroid Treatment for Hypereosinophilic Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01524536·26 enrolled
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
Completed·GSK logoGSK·Phase 3·NCT03306043·102 enrolled
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00017862·10 enrolled
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00483067·13 enrolled
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Completed·GSK logoGSK·Phase 3·NCT02836496·108 enrolled
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Completed·NNorthern Italy Leukemia Group·Phase 2·NCT00787384·25 enrolled
Identification of New Markers in the Hypereosinophilic Syndrome
Completed·UUniversity Hospital, Lille·N/A·NCT01713504·41 enrolled
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Completed·GSK logoGSK·Phase 3·NCT00086658·86 enrolled
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Completed·—·Phase 1/2·NCT00266565·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)